Filter Results:
(128)
Show Results For
- All HBS Web
(380)
- People (2)
- News (141)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (72)
Show Results For
- All HBS Web
(380)
- People (2)
- News (141)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (72)
Sort by
- 19 Sep 2012
- Research & Ideas
Book Excerpt: “The Architecture of Innovation”
but the fund achieved impressive successes. For instance, it invested in biotech firms like Amgen, Cephalon, and Sepracor, and coinvested with major venture firms such as Kleiner Perkins and New Enterprise Associates. Its compensation... View Details
- 28 Apr 2009
- First Look
First Look: April 28, 2009
testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Martha Lagace
- 26 Nov 2001
- Research & Ideas
Women Entrepreneurs Use Springboard for Funding
personalize healthcare and benefits, and Carol Nacy of Sequella, Inc., a biotech firm focused on controlling global infectious diseases, especially tuberculosis. Most of the companies were already up and running. Their funding to date has... View Details
Keywords: by Martha Lagace
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
science-based research is something the heads of top biotech and pharmas learned long ago: There are few instant payoffs to please investors. Just ask Raymond Gilmartin, former chairman, president, and CEO of Merck & Co., who now... View Details
- 17 Dec 2001
- Research & Ideas
Enterprising Women
by the firm's mission and saw that it had been self-sufficient for nearly seven years, Fisher's task became much easier: In three stages, over the course of 2000, she raised venture capital funds of $11 million, $48 million, and $75 million. That same year, she founded... View Details
Keywords: by Julia Hanna
- 29 Oct 2000
- Research & Ideas
The Entrepreneurial Venture: A Conversation
decisions? O'Lear: I have been involved in microeconomic (company specific) upheaval. Prior to starting a company with two others, I worked at two high-tech companies: a privately held cardiac ultrasound imaging company and a VC-backed View Details
Keywords: by Susan Young
- 20 Jul 2015
- Research & Ideas
Globalization Hasn’t Killed the Manufacturing Cluster
the federal government to create new clusters in the United States. He points to the rise of biotech in Harvard's backyard, which began despite government opposition in the 1970s. Clusters "tend to emerge much more organically, and they... View Details
- 06 Feb 2007
- First Look
First Look: February 6, 2007
Harvard Business School Supplement 107-049 Supplements the (A) case. Purchase this supplement: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=107049 Monsanto: Realizing Biotech Value in Brazil Harvard Business School Case... View Details
Keywords: Martha Lagace
- 17 Oct 2006
- First Look
First Look: October 17, 2006
founded by a young venture capitalist and a university professor to exploit recombinant DNA technology. Thirty years and more than $300 billion in investments later, only a handful of biotech firms have matched Genentech's success or even... View Details
Keywords: Sean Silverthorne
- 10 May 2017
- Research & Ideas
Amazon Web Services Changed the Way VCs Fund Startups
cloud-based software and service companies, which could take advantage of AWS to decrease costs, versus others like biotechs that were less impacted by the new technologies. “The goal was to try and understand whether VCs were allocating... View Details
- 16 Feb 2004
- Research & Ideas
HBS Center Focuses on Europe
growth decisions facing Direvo, a young German biotech firm, when one of their partners suddenly wants to become an investor and the company expands both its customer and investor base in Europe and not just in Germany. Still a relatively... View Details
Keywords: by Cynthia Churchwell
- 19 Mar 2006
- Research & Ideas
Unlocking Your Investment Capital
Neither an asset's cost nor its size specifies its riskiness. For example, consider two assets, $1 billion of a single-drug biotech stock and $1 billion of U.S. Treasury bonds: Each has the same cost and size but they have radically... View Details
- 01 May 2007
- First Look
First Look: May 1, 2007
drug development process; threats from biotech and generics competitors; pharmaceutical manufacturing, selling, and marketing; and pharmaceutical consumption in Europe, the third world, and the U.S. Merck and Pfizer are analyzed in-depth... View Details
Keywords: Sean Silverthorne
- 08 Sep 2010
- First Look
First Look: September 8, 2010
for a cure; the doubts and obstacles he experiences along the way; and the current options Kremer faces, from returning home to spend time with family to founding a new biotech venture. Through this stark, realistic, and inspiring... View Details
Keywords: Sean Silverthorne
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
prescription drugs that in 1992 it spun off its remaining chemical business to its stockholders. In addition, the American Cyanamid purchase included Immunex, one of the very few biotech startups that had surpassed $100 million in... View Details
- 07 Oct 2014
- First Look
First Look: October 7
(MMRC), and brought together a diverse body of academics, researchers, pharmaceutical and biotech companies, physicians, and patients to combine their efforts around the disease. The MMRF had helped facilitate clinical trials for... View Details
Keywords: Sean Silverthorne
- 25 Feb 2014
- First Look
First Look: February 25
recent firm performance? Purchase this case: http://hbr.org/product/say-on-pay-qualcomm-inc-shareholders-vote-maybe-in-2012/an/114005-PDF-ENG Harvard Business School Case 213-047 Aqua Bounty Valuation of a pre-revenue biotech company at... View Details
Keywords: Sean Silverthorne
- 17 Mar 2009
- First Look
First Look: March 17, 2009
Download the paper: http://www.hbs.edu/research/pdf/09-099.pdf Cases & Course MaterialsAvid Radiopharmaceuticals: The Venture Debt Question Harvard Business School Case 809-086 The CEO of a promising biotech company must decide how... View Details
Keywords: Martha Lagace
- 07 Feb 2017
- First Look
First Look at New Research: February 7
case:https://cb.hbsp.harvard.edu/cbmp/product/517027-PDF-ENG Harvard Business School Case 617-022 Alnylam Pharmaceuticals: Building Value from the IP Estate (B) The leader of a pioneering biotech company in the siRNA space weighs his... View Details
Keywords: Sean Silverthorne
- 03 May 2011
- First Look
First Look: May 3
Business Model Gary P. Pisano, Ryan Johnson, and Carin-Isabel KnoopHarvard Business School Case 611-046 In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this... View Details
Keywords: Sean Silverthorne